液体活检RET突变分析指导散发性甲状腺髓样癌RET抑制剂治疗
该回顾性队列研究分析36例RET突变散发性甲状腺髓样癌患者的血浆ctDNA,采用特异性数字微滴PCR检测RET驱动突变。结果显示进展组16/18检出RET突变ctDNA,而稳定组0/9检出,且检出与疾病进展、高肿瘤负荷及降钙素、癌胚抗原升高相关。提示肿瘤组织不可及时,液体活检RET突变分析在高肿瘤负荷且疾病进展的散发性甲状腺髓样癌中有应用价值。
要点
- 进展期散发性甲状腺髓样癌ctDNA RET突变检出率高于稳定期患者
- ctDNA检出与疾病进展、转移灶超过五个及降钙素和癌胚抗原升高相关
- 组织不可及时可考虑液体活检指导RET抑制剂治疗,但应在高肿瘤负荷且进展时进行
核心结论
- 血浆ctDNA分析可用于散发性甲状腺髓样癌患者的基因分型。
- 当原发肿瘤组织不可获得或不足以提取高质量核酸时,基于液体活检的RET突变分析对晚期进展性散发性甲状腺髓样癌可能有益,有助于按特定适应证启用RET抑制剂治疗。
- 为获得可靠结果,ctDNA分子分析应在肿瘤负荷高且疾病进展时进行。
研究设计与样本
- 回顾性队列研究,分析36例RET突变散发性甲状腺髓样癌患者的血浆。
- 患者分为三组:18例进展性散发性甲状腺髓样癌;9例接受多激酶抑制剂治疗下疾病稳定;9例转移但稳定且未治疗。
- 第1组检测进展时、开始全身治疗前的血浆,第2、3组检测随访时最后一次可用血浆;用特异性数字微滴PCR分析ctDNA中的RET驱动突变。
主要发现
- 36份ctDNA样本中检出RET驱动突变16/36(44.4%,CI 27.9-61.9)。
- 三组间差异有统计学意义:第1组16/18(88.9%,CI 65.3-98.6),第2、3组0/9(0%,CI 0-33.6),p < 0.001;平均变异等位基因频率为5.4%。
- 可检出RET突变ctDNA与疾病进展(p < 0.001)、转移灶超过五个病灶的比例更高(即肿瘤负荷,p = 0.001)、血清降钙素水平更高(p = 0.009)及癌胚抗原更高(p = 0.038)相关。
关键数值与推荐
- RET突变ctDNA检出率:总体16/36(44.4%,CI 27.9-61.9);进展组16/18(88.9%,CI 65.3-98.6);稳定组0/9(0%,CI 0-33.6),组间p < 0.001。
- 可检出RET突变ctDNA的平均变异等位基因频率为5.4%。
- ctDNA检出与疾病进展(p < 0.001)、转移灶超过五个(p = 0.001)、降钙素升高(p = 0.009)、癌胚抗原升高(p = 0.038)相关。
临床怎么用
- 对肿瘤组织不可获得或核酸质量不足的散发性甲状腺髓样癌患者,可考虑血浆ctDNA检测RET突变以指导RET抑制剂治疗。
- ctDNA分子分析宜在高肿瘤负荷且疾病进展时进行,以提高检出可靠性。
- ctDNA检出RET突变时应结合疾病进展、转移灶数量及降钙素、癌胚抗原水平综合评估。
- 稳定期或低肿瘤负荷患者不宜依赖ctDNA阴性结果排除RET突变。
局限性
- 为回顾性队列研究,样本量36例,分组后各组例数较少。
- 仅分析RET突变散发性甲状腺髓样癌患者,未涉及其他驱动基因或RET野生型人群。
- 采用特异性数字微滴PCR检测已知RET驱动突变,未评估其他检测方法或未知突变。
- 第2、3组检测随访时最后一次血浆,与第1组采血时机不同,可能影响组间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One of the challenges in tumor molecular profiling for therapeutic decisions is the unavailability of tumor tissue or its inadequacy to provide high-quality nucleic acids. Although tissue biopsy remains the "gold-standard," analysis of circulating tumor DNA (ctDNA) may offer an alternative to characterize mutations necessary to initiate systemic therapy with selective inhibitors in eligible patients. This study aimed to identify cases of sporadic medullary thyroid carcinoma (sMTC) in which plasma ctDNA analysis may be useful for RET gene testing when tumor tissue is unavailable. METHODS: We conducted a retrospective cohort study analyzing plasma from 36 patients affected by RET-mutated sMTC. Patients were divided into three cohorts (1) 18 patients with progressive sMTC; (2) nine patients with stable disease under treatment with a multikinase inhibitor; and (3) nine patients with metastatic but stable disease without treatment. For patients in cohort 1, we studied plasma collected at the time of progression just before the initiation of systemic therapy, while in cohorts 2 and 3, we studied last plasma available at follow-up. The RET driver mutation was analyzed in ctDNA using specific digital droplet PCR assays. RESULTS: The RET driver mutation was detected in 16/36 (44.4%, CI 27.9-61.9) ctDNA samples, with a statistically significant difference among the three cohorts 16/18 (88.9%, CI 65.3-98.6) in cohort 1 and 0/9 (0%, CI 0-33.6) in cohorts 2 and 3 (p < 0.001) with a mean variant allele frequency of 5.4%. The presence of detectable RET-mutated ctDNA was associated with disease progression (p < 0.001), higher percentage of metastatic sites with > five lesions (i.e., tumor burden; p = 0.001), and higher levels of serum calcitonin (Ct) (p = 0.009), and carcinoembryonic antigen (p = 0.038). CONCLUSIONS: Our study demonstrates that ctDNA analysis may be a valid approach to genotype sMTC patients. Thus, liquid biopsy-based RET mutation profiling may be beneficial in advanced and progressive sMTC cases when primary tumor tissue is unavailable or inadequate for high-quality nucleic acid extraction, enabling RET-inhibitor therapy, if needed, according to specific indications. However, to obtain reliable results, ctDNA molecular profiling should be performed when tumor burden is high and the disease is progressing.
引用
- Ciampi R, Casalini R, Ramone T, et al. Liquid Biopsy-Based RET Mutation Profiling to Guide RET Inhibitor Treatment in Sporadic Medullary Thyroid Carcinoma May Be Useful in Cases with High Tumor Burden and Progressive Disease. Thyroid. 2026. PMID: 41578741. doi:10.1177/10507256261416836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。